Drug Approvals, Trial Results, and Collaboration- Research Report on Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly, AbbVie, and GSK

Mon Sep 30, 2013 8:01am EDT

* Reuters is not responsible for the content in this press release.

Drug Approvals, Trial Results, and Collaboration- Research Report on Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly, AbbVie, and GSK

PR Newswire

NEW YORK, September 30, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb Company (NYSE: BMY), Eli Lilly & Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), and GlaxoSmithKline plc (NYSE: GSK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On September 23, 2013, Janssen-Cilag International NV,a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it has received an approval from the European Commission for the use of STELARA (ustekinumab), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Jerome A. Boscia, M.D., Vice President, Head of Immunology Development, Janssen Research & Development, stated, "The European Commission approval of STELARA for the treatment of active psoriatic arthritis brings an important new therapeutic option to patients and marks the first treatment approved for this devastating and complex disease since the introduction of anti-tumor necrosis factor (TNF)-alpha agents." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-25/JNJ]

Bristol-Myers Squibb Company Research Report

On September 24, 2013, Bristol-Myers Squibb Company (Bristol-Myers) and AstraZeneca announced results from a Phase III study evaluating dapagliflozin in adult patients with type 2 diabetes who were inadequately controlled on combination treatment with metformin plus sulfonylurea. Bristol-Myersreported that patients treated with dapagliflozin 10 mg as an add-on therapy to metformin plus sulfonylurea demonstrated significant improvements in glycosylated hemoglobin levels (HbA1c) and, among key secondary endpoints, significant reductions in fasting plasma glucose (FPG) and in body weight compared to placebo at 24 weeks. The Company stated that marked improvements were also observed in seated systolic blood pressure (SBP) at eight weeks in patients treated with dapagliflozin compared to placebo. Bristol-Mayers informed that the results were presented on the announcement date at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain.The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-25/BMY]

Eli Lilly & Company Research Report

On September 24, 2013, Eli Lilly & Company (Lilly) and Boehringer Ingelheim announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the safety of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin in adults with type 2 diabetes (T2D). Lilly reported that findings from a pooled, post-hoc analysis of safety data from 22 linagliptin clinical trials with 7,400 adults with T2D (4,810 received linagliptin, 2,590 received placebo) showed that the hypoglycemic incidence rate for linagliptin compared with placebo was 11.5% vs. 14%, respectively, and overall incidence of adverse events (AE) or serious adverse events (SAE) with linagliptin was similar to placebo (AE 56.5% versus 61.2%, and SAE 4.8% versus 6.3%, respectively). Commenting on the renal safety data in the elderly, Christophe Arbet-Engels, MD, PhD, Vice President, Metabolic Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, said, "The results from these pooled analyses continued to demonstrate that linagliptin is a treatment option for a wide range of adults with type 2 diabetes, including the elderly and those with renal impairment." The Full Research Report on Eli Lilly and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-25/LLY]

AbbVie Inc. Research Report

On September 24, 2013, AbbVie Inc. (AbbVie) announced that it has entered into a global alliance with Galapagos NV for the discovery, development, and commercialization of novel potentiator and combination therapies in cystic fibrosis (CF). Jim Sullivan, Ph.D., Vice President, Pharmaceutical Discovery, AbbVie, commented, "We're pleased to enhance our partnership with Galapagos to include research in cystic fibrosis, a debilitating disease with significant unmet medical need. Our knowledge of the patient experience, combined with innovative advances in the understanding of disease etiology, offers the potential for new transformational treatments." The Company also informed that in the alliance, AbbVie and Galapagos will develop potentiators and correctors discovered by Galapagos with the aim to initiate Phase 1 clinical studies at the end of 2014.The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-25/ABBV]

GlaxoSmithKline plc Research Report

On September 20, 2013, GlaxoSmithKline plc (GSK) and Theravanceannounced that Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR ELLIPTA, for the treatment of bronchial asthma (in cases where concurrent use of inhaled corticosteroid and long-acting inhaled beta2 agonist is required). According to the Company, RELVAR ELLIPTAis not indicated for the treatment of chronic obstructive pulmonary disease (COPD) in Japan. Darrell Baker, Senior Vice President and Head, GSK Global Respiratory Franchise, said, "The approval of Relvar Ellipta in Japan means that, for the first time, people with asthma will be able to benefit from a once-daily ICS/LABA that delivers continuous 24-hour efficacy. Throughout the development programme, GSK focused on the needs of patients to develop a medicine that may help address some of the existing treatment challenges. We are delighted by this approval, which means that healthcare professionals in Japan will soon have another treatment option for appropriate asthma patients." The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-25/GSK]


  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by NamrataMaheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investors' Reports

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.